Canopy Growth (NYSE: CGC) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it compare to its rivals? We will compare Canopy Growth to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares Canopy Growth and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Canopy Growth $297.34 million -$993.37 million 10.64
Canopy Growth Competitors $218.50 million -$99.79 million 2.20

Canopy Growth has higher revenue, but lower earnings than its rivals. Canopy Growth is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Canopy Growth and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Canopy Growth -439.18% -21.30% -15.22%
Canopy Growth Competitors -163.69% -267.59% -46.37%

Analyst Ratings

This is a summary of current ratings and price targets for Canopy Growth and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth 3 13 4 1 2.14
Canopy Growth Competitors 135 359 403 14 2.32

Canopy Growth presently has a consensus target price of $28.69, indicating a potential upside of 104.17%. As a group, “Medicinals & botanicals” companies have a potential upside of 123.82%. Given Canopy Growth’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Canopy Growth has less favorable growth aspects than its rivals.

Risk and Volatility

Canopy Growth has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500. Comparatively, Canopy Growth’s rivals have a beta of 2.56, suggesting that their average stock price is 156% more volatile than the S&P 500.

Institutional & Insider Ownership

9.2% of Canopy Growth shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 0.3% of Canopy Growth shares are owned by insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Canopy Growth rivals beat Canopy Growth on 9 of the 13 factors compared.

Canopy Growth Company Profile

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada to investigate the efficacy of cannabinoids for the treatment of post-concussion neurological diseases in former NHL players; and partnership with Parent Action on Drugs. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.